Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Males and Females at least 18 years of age * Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery * ECOG Performance status of 0 or 1 * Available tumor sample for testing * Acceptable blood work Exclusion Criteria: * Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas * Prior chemotherapy for pleural mesothelioma * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody * History of other malignancy unless the subject has been disease-free for at least 3 years * Active, untreated central nervous system (CNS) metastasis Other protocol defined inclusion/exclusion criteria could apply